Dr. Chang is a thoracic radiation oncologist with more than 30 years of clinical and research experience. He holds a tenured Texas 4000 Distinguished Professorship and Director of Stereotactic Ablative Radiotherapy Program at MD Anderson Cancer Center. He is an appointed American Society of Radiation Oncology Fellow and have been recognized with the Best Doctors of America award. He is a voting committee member of NCCN thoracic guidelines and chair both the international proton therapy PTCOG thoracic and American Radium Society Thoracic AUC committees. His clinical intertest has been focused on lung cancer, esophageal cancer, thymoma, mesothelioma using image-guided radiotherapy, including IMRT, VMAT, SBRT/SABR, radiosurgery, proton therapy combined with novel systemic therapy such as chemotherapy, immunotherapy, targeted therapy and etc. He is one of the pioneers in the field of stereotactic ablative radiotherapy (SABR), proton therapy and immunotherapy for lung cancer. His research has helped to establish the role of SBRT/SABR, proton therapy, and combined immunotherapy and SABR (I-SABR) in lung cancer. Additionally, on behalf of national and international societies, he has led several important consensus statements that have significantly impacted the radiation oncology community about SABR, proton therapy in lung cancer, IMPT in moving thoracic cancers, management of small cell lung cancer, oligometastasis, and re-irradiation of thoracic cancer.